Study to Evaluate the Effects of Single Ascending Oral Doses of ACD856 on Safety, Tolerability and Pharmacokinetics

Inclusion Criteria

• •Signed and dated informed consent prior to any study-mandated procedure.´
• •Willing and able to comply with study requirements.
• •Healthy males and healthy women of non-childbearing potential aged ≥18 and \<65 years at screening.
• •BMI ≥18.0 and ≤30.0 kg/m2 at screening.
• •Males and females of non-childbearing potential may be included in the study. Male subjects must be willing to use condom or be vasectomized or practice sexual abstinence to prevent pregnancy and drug exposure of a partner and refrain from donating sperm from the date of dosing until 3 months after dosing with the IMP.
• •Clinically acceptable medical history, physical findings, vital signs, ECG and laboratory values at the time of screening, as judged by the Investigator.